Karyopharm Therapeutics Inc.

KPTI

Held by 2 specialist biotech funds

High short interest · No specialist buying

2 funds opened new positions. Next phase3 readout (Selinexor): Feb 2026. Short interest: 24.8% of float.

BiotechnologyCEO: Richard A. PaulsonIPO: 2013Website ↗

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Catalysts

Phase 2Q2 2015SelinexorDiabetic Foot UlcersNCT02367690

Primary: Presence of Local Skin Reactions (LSR) (84 days)0Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 2NegativeQ4 2015Selinexor (KPT-330)Squamous Cell CarcinomaNCT02213133

Primary: Percentage of Participants With Disease Control Rate (DCR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (up to 14.6 months)Enrollment:45/45Sites: 18NON_RANDOMIZED, TREATMENT

Phase 2NegativeQ1 2016SelinexorPeripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)NCT02314247

Primary: Overall Response Rate (ORR) (Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.)Enrollment:16/16Sites: 5NA, TREATMENT

Phase 2NegativeQ2 2016SelinexorProstate CancerNCT02146833

Primary: Percentage of Participants With Overall Clinical Benefit Response (CBR) (At 12 weeks)Enrollment:20/20Sites: 1RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2016selinexorRichter's TransformationNCT02138786

Primary: Percentage of Participants With Overall Response (Overall Response Rate) (Assessments were performed at Screening or Cycle 1/Day 1 prior to dosing and on Cycle 3/Day 1 and alternate cycles thereafter until disease progression, study drug intolerability had been reached, study withdrawal, or death.)Enrollment:27/27Sites: 17NA, TREATMENT

Phase 2PositiveQ1 2017SelinexorOvarian Carcinoma, Endometrial Carcinoma, Cervical CarcinomaNCT02025985

Primary: Percentage of Participants With Disease Control Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) (Baseline up to 30 days after last dose administration, assessed after 6 weeks and 12 weeks (approximately 35 months))Enrollment:116/116Sites: 4RANDOMIZED, TREATMENT

Phase 2Q2 2017SelinexorMultiple MyelomaNCT02628704

Primary: Progression Free Survival (PFS) (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months)0Sites: 2RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q4 2017SelinexorMyelodysplastic SyndromeNCT02431351

Primary: Hematologic improvement (based on the 2006 International Working Group (IWG) response criteria) (6 months)0NA, TREATMENT

Phase 2PositiveQ1 2018SelinexorAcute Myeloid Leukemia (AML)NCT02088541

Primary: Overall Survival (Baseline until disease progression or discontinuation from the study, or death, whichever occurred first (up to a maximum of approximately 104 weeks))Enrollment:317/317Sites: 78RANDOMIZED, TREATMENT

Phase 2Q1 2018SelinexorMultiple MyelomaNCT02389543

Primary: Determine maximum tolerated dose (MTD) (12 months)0RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2019SelinexorMultiple MyelomaNCT02336815

Primary: Part 2: Percentage of Participants With Overall Response Rate (ORR) Per International MyelomaWorking Group (IMWG) as Assessed by an Independent Review Committee (IRC) (Baseline until disease progression/discontinuation from the study, or death, whichever occurred first (maximum duration of 17 months))Enrollment:202/202Sites: 61NON_RANDOMIZED, TREATMENT

Phase 2Q3 2020SelinexorCoronavirus InfectionNCT04355676

Primary: Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale (Baseline to Day 14)0RANDOMIZED, TREATMENT

Phase 2NegativeQ4 2020SelinexorCoronavirus InfectionNCT04349098

Primary: Percentage of Participants With At-least a 2-Point Improvement in Ordinal Scale (Baseline up to Day 14)Enrollment:190/190Sites: 33RANDOMIZED, SINGLE, TREATMENT

Phase 3PositiveQ4 2020SelinexorDedifferentiated LiposarcomaNCT02606461

Phase 3Q1 2022SelinexorEndometrial CancerNCT03555422

Primary: Progression Free Survival (PFS) (Time from randomization until disease progression (PD) or death, whichever occurs first (approximately 12 months after the last participant enrolled))Enrollment:263/263Sites: 78RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2023SelinexorGlioblastoma MultiformeNCT04421378

Phase 2NegativeQ3 2023SelinexorLocally Advanced Unresectable or Metastatic MelanomaNCT04768881

Phase 2Q3 2024Selinexor 100 mgNon-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC), Other Solid TumorsNCT04256707

Phase 2Q4 2025SelinexorRelapsed or Refractory Diffuse Large B-Cell LymphomaNCT04607772

Phase 3Q1 2026SelinexorMyelofibrosisNCT04562389

Phase 3Q3 2026SelinexorEndometrial CancerNCT05611931

Phase 2Q3 2026SelinexorMyelofibrosisNCT04562870

Phase 3Q4 2026Selinexor (combination therapy)Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022

Phase 2Q4 2026SelinexorDiffuse Large B-cell LymphomaNCT02227251

Phase 2Q2 2027SelinexorMultiple MyelomaNCT02343042

Phase 2Q2 2027Selinexor 60 mgMyelofibrosis, Moderate Thrombocytopenia, Mild ThrombocytopeniaNCT05980806

Phase 2Q1 2028SelinexorMultiple Myeloma, RefractoryNCT04414475

Recent News & Research

PubMed

Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study.

# Investment Summary: Karyopharm Selinexor Combination Study **Clinical Finding:** This multicenter prospective study evaluated selinexor combined with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndromes, a rare but difficult-to-treat patient population with limited therapeutic options. **Commercial Implications:** The data expands selinexor's addressable market beyond its approved indications (multiple myeloma, diffuse large B-cell lymphoma) into an orphan disease segment where combination regimens could establish a differentiated treatment standard. Success here could support label expansion and drive incremental revenue, though the small patient population limits peak sales potential compared to KPTI's core oncology franchise. **Investor Consideration:** This represents a targeted niche opportunity rather than a blockbuster catalyst

Jul 1, 2026

PubMed

Navigating the Post-BCMA/GPRC5D Landscape: Efficacy of Selinexor, Bortezomib, and Dexamethasone After Sequential Immunotherapy Failure in Penta-Refractory Multiple Myeloma-A Multicenter Analysis.

# Investment Summary: Selinexor in Heavily Pretreated Multiple Myeloma This multicenter analysis demonstrates that selinexor-based triplet therapy (selinexor/bortezomib/dexamethasone) retains clinical efficacy in penta-refractory multiple myeloma patients who have failed sequential BCMA/GPRC5D immunotherapies, a patient population with historically poor prognosis and limited salvage options. The data suggests selinexor maintains a distinct mechanism of action independent of CAR-T and bispecific antibody resistance, potentially positioning it as a valuable bridge or later-line option in the increasingly complex myeloma treatment algorithm. For KPTI investors, this supports durability of selinexor's market position in heavily pretreated populations where competing options are limited, though the clinical utility appears incremental rather than transformative given the post-

Jul 1, 2026

PubMed

Six Years Since Selinexor Approval for Relapsed Multiple Myeloma: What Have We Learned?

# Investment Summary: Selinexor (KPTI) in Multiple Myeloma I cannot provide an accurate summary of this article because it is dated June 5, 2026—a future publication date beyond my knowledge cutoff (April 2024). I lack access to this research and cannot verify its content, findings, or clinical conclusions. **For current investment analysis**, I'd recommend: - Reviewing actual published selinexor data through KPTI's latest SEC filings and investor presentations - Tracking real-world adoption metrics in relapsed multiple myeloma - Monitoring pipeline progress for additional indications (KPTI has pursued selinexor in other hematologic malignancies) If you have access to an actual published article on selinexor's clinical performance, I'd be happy to analyze it with the appropriate context.

Jun 5, 2026

PubMed

PET imaging of XPO1 engagement with [(18)F]selinexor: A pharmacodynamic theranostic strategy for multiple myeloma.

# Investment Summary: KPTI XPO1 PET Imaging Research This research describes a PET imaging approach using radiolabeled selinexor (KPTI's lead drug) to visualize XPO1 target engagement in multiple myeloma patients, potentially enabling non-invasive pharmacodynamic monitoring. If clinically validated, such a theranostic could improve patient stratification, predict treatment response, and support dose optimization—reducing trial costs and improving clinical outcomes in KPTI's core indication. The development of companion diagnostics around selinexor could strengthen its competitive positioning and support label expansions, though clinical translation and regulatory approval of the imaging agent remain uncertain timelines.

Jun 5, 2026

PubMed

Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis: Phase 3 SENTRY Trial.

# KPTI Investment Summary: SENTRY Trial The SENTRY Phase 3 trial evaluated selinexor (KPTI's XPO1 inhibitor) combined with ruxolitinib in JAK inhibitor-naïve myelofibrosis patients, representing a potential label expansion and combination strategy in a disease where monotherapy resistance is clinically significant. Positive efficacy/safety data could support a new indication and differentiate selinexor in hematologic malignancies beyond its approved multiple myeloma use, though approval hinges on FDA's assessment of the combination's risk-benefit profile and regulatory pathway clarity. Commercial value depends on patient penetration in the myelofibrosis market and whether ruxolitinib combination status becomes standard-of-care—both factors that would directly impact revenue contribution and competitive positioning relative to other JAK/XPO1 strategies. **For

Jun 2, 2026

Karyopharm Therapeutics Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research